Diabetes mellitus complicating systemic lupus erythematosus – analysis of the UCL lupus cohort and review of the literature

Abstract

Systemic lupus erythematosus (SLE) often coexists with other diseases. Diabetes mellitus (DM) is an example and patients with overlap SLE-DM can present with clinical features common to both disorders. In this review, we describe the patients with overlap SLE-DM, focussing on the clinical features common to both diseases that these patients can present, and on the challenges of managing such complications. A detailed review of the patients’ notes (n = 485) was performed. At every outpatient appointment the patients’ urine was tested for glucose, protein and blood. Patients with persistent glycosuria were investigated with fasting blood glucose and a glucose tolerance test to help make the diagnosis of DM. Particular note was made of those patients whose symptoms could be due to SLE, DM or both. Nine patients with DM were identified. Three had type 1 DM, four had type 2 DM and two were considered to have steroid-induced DM. Among these patients, three had renal involvement (two with WHO class IV lupus nephritis); two had peripheral neuropathy (one had a mixed sensory and motor neuropathy, one had a sensory peripheral neuropathy); two patients had retinopathy and cataracts and one had angina. The combination of SLE and DM is uncommon but the predisposition to renal, peripheral neuropathy and retinal disease means that great care must be taken when deciding which clinical feature is due to which disease, because active SLE requires additional immunosuppression whereas DM requires optimization of the metabolic control. Interestingly, although in theory patients with SLE and DM are in double-jeopardy of developing atherosclerosis, to date, only one of our overlap patients has developed angina.

Keywords

diabetes nephropathy neuropathy retinopathy SLE

Get full access to this article

View all access options for this article.

References

1 Chambers S Charman SC Rahman A Isenberg DA . Development of additional autoimmune diseases in a multiethnic cohort of patients with reference to damage and mortality. Ann Rheum Dis 2007; 66: 1123–1127.

2 Buyon J Wallace DJ . The use of exogenous estrogens, endocrine system and urogenital tract. In: DJ Wallace BH Hahn , (eds), Dubois’ Lupus Erythematosus, sixth ed. Philadelphia: Lippincott, Williams & Wilkins. p. 821–841.

3 Maksimowicz-McKinnon K Manzi S . Cardiovascular manifestations of lupus. In: DJ Wallace BH Hahn , (eds), Dubois‘ Lupus Erythematosus, seventh ed. Philadelphia: Lippincott; 2007. p. 674.

4 Tan EM Cohen AS Fries JF . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

5 American Diabetes Association . Diagnosis and Classification of Diabetes mellitus. Diabetes Care 2007; 30: S42–S47.

6 Adler M Chambers S Edwards C . An assessment of renal flare in an SLE cohort with special reference to ethnicity overall 25 year period. Rheumatology 2006; 45: 1144–1147.

7 Marto N Bertolaccini ML Calabuig E . Anti-C1q antibodies in nephritis:correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 444–448.

8 Ritz E . Diabetic nephropathy. Saudi J Kidney Dis Transpl 2006; 17: 481–490.

9 Tone A Shikata K Matsuda M . Clinical features of non-diabetic renal diseases in patients with type 2 diabetes. Diabetes Res Clin Pract 2005; 69: 237–242.

10.

10 West SG . The nervous system. In: DJ Wallace BH Hahn , (eds), Dubois’ Lupus Erythematosus, sixth ed. Philadelphia: Lippincott; 2007. p. 695.

11.

11 Bril V . Status of current clinical trials in diabetic polyneuropathy. Can J Neurol Sci 2001; 28: 191–198.

12.

12 Omdal R Loseth S Torbergsen T . Peripheral neuropathy in systemic lupus erythematosus – a longitudinal study. Acta Neurol Scand 2001; 103: 386–391.

13.

13 Grassi G . Diabetic retinopathy. Minerva Med 2003; 94: 419–435.

14.

14 Au A O'Day J . Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: associations, visual outcomes, complications and treatment. Clin Exp Ophthalmol 2004; 32: 87–100.

15.

15 Trojet S Loukil I El Afrit MA . Bilateral retinal vascular occlusion during antiphospholipid antibody syndrome: a case report. J Fr Ophtalmol 2005; 28: 503–507.

16.

16 Ermakova NA Alekberova ZS Kosheleva NM Reshetniak TN . Characteristics of retinal vascular involvement in systemic lupus erythematosus. Vestn Oftalmol 2001; 117: 21–24.

17.

17 Bruce I . ‘Not only...but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatol 2005; 44: 1492–1502.

18.

18 Coccheri S . Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 2007; 67: 997–1026.